Axial Biotherapeutics
Prudential Center
800 Boylston Street,15th Floor
Boston
Massachusetts
02199
United States
Website: http://www.axialbiotherapeutics.com/
About Axial Biotherapeutics
Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and Central Nervous System to develop a new class of therapeutics to improve the quality of life for people with CNS diseases and disorders.YEAR FOUNDED:
November 2016
LEADERSHIP:
Co-Founder, CEO and Director: David H. Donabedian, Ph.D.
Co-Founder and Director: Sarkis Mazmanian, Ph.D.
30 articles about Axial Biotherapeutics
-
Axial Biotherapeutics Appoints Federico Bolognani, M.D., Ph.D., Vice President and Head of Clinical Science
9/22/2020
Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced the appointment of Federico Bolognani, M.D., Ph.D. to the newly-created position of Vice President and Head of Clinical Science, effective November 2, 2020.
-
Axial Biotherapeutics to Present at The JMP Securities CNS Forum
8/17/2020
Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that management will participate in a fireside chat at The JMP Securities CNS Forum on Wednesday, August 19, 2020 at 2:00 PM ET. About Axial Biotherapeutics Axial Biotherapeutics is a clinical stage biopharmaceutical comp
-
Axial Biotherapeutics Announces a Research Grant Award from The Michael J. Fox Foundation for the Development of an Enteric Nervous System Model to Assess Novel Parkinson’s Disease Therapeutics
7/28/2020
Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted therapeutics for neurodegenerative diseases and neurodevelopmental disorders, today announces it has received a research grant of $440,000 from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through its Therapeutic Pipeline Program. The award will enable development of a novel in vitro model system of the e
-
Axial Biotherapeutics to Present at the Jefferies Virtual Global Healthcare Conference
5/27/2020
Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that the David H. Donabedian, Ph.D., Co-founder and Chief Executive Officer of Axial Biotherapeutics will present a company overview at the Jefferies Virtual Global Healthcare Conference on Wednesday, June 3, 2020 at 4:30 PM ET. A
-
Axial Biotherapeutics to Present Virtual Presentation at American Society of Clinical Psychopharmacology (ASCP) 2020 Annual Meeting
5/22/2020
Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced the upcoming virtual presentation on the development of novel therapeutics focused on treating Central Nervous System (CNS) indications via the gut-brain axis at the American Society of Clinical Psychopharmacology (ASCP) 2020 Annual Mee
-
Axial Biotherapeutics Announces Positive Topline Results from Phase 1b/2a Clinical Trial of AB-2004 for the Treatment of Autism Spectrum Disorder
4/2/2020
Axial Biotherapeutics announced positive topline data from its Phase 1b/2a clinical trial of AB-2004, a first-in-class therapeutic that removes certain metabolites from the gastrointestinal tract for the treatment of Autism Spectrum Disorder.
-
Axial Biotherapeutics to Present at the Chardan 2nd Annual Microbiome Medicines Virtual Summit
3/10/2020
Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that David H. Donabedian, Ph.D., Co-founder and Chief Executive Officer of Axial Biotherapeutics will present a virtual company overview a
-
Axial Biotherapeutics Strengthens and Expands Board of Directors and Leadership Team
2/12/2020
Feb. 12, 2020 13:00 UTC -Dr. Scott C. Brun joins Axial Board to support the advancement of the Company’s Autism and Parkinson’s Programs- WALTHAM, Mass.--( BUSINESS WIRE )-- Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced the appointment of Scott Brun M.D. to its Board of Directors. In addition, the Company announced the promotions an
-
Axial Biotherapeutics to Present at the Centre for Clinical Trials in Rare Neurodevelopmental Disorders’ Emerging Management Therapies for Childhood Neurodevelopmental Disorders Scientific Symposium
2/5/2020
Axial Biotherapeutics, today announced that Stewart Campbell, Ph.D., Senior Vice President, Research & Development, will present a translational overview of Axial’s Autism program at the Centre for Clinical Trials in Rare Neurodevelopmental Disorders’ (CCTRND) Emerging Management Therapies for Childhood Neurodevelopment Disorders
-
Axial Biotherapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
11/26/2019
Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that the company will present a company overview at the 31st Annual Piper Jaffray Healthcare Conference on Tuesday, December 3, 2019 at 1:10 PM ET in New York, NY
-
Axial Biotherapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial Evaluating AB-2004 in Patients with Autism Spectrum Disorder
11/18/2019
Axial Biotherapeutics announced the completion of enrollment in its Phase 1b/2a clinical trial evaluating AB-2004.
-
Axial Biotherapeutics Presents Preclinical Data on Microbiome-Derived Metabolites Associated with Autism Spectrum Disorder at the Society for Neuroscience 2019 Annual Meeting
10/18/2019
Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that Dr. Torsten Madsen, acting Chief Medical Officer will be presenting preclinical data highlighting the strong association between bacteria-derived metabolites and autism spectrum disorder (ASD) at the Society for Neuroscience 2019 Annual Meeting on Saturday, October 19, 2019 in Chicago, IL.
-
Axial Biotherapeutics to Participate in 5th Annual BMO Private Company Showcase
10/11/2019
Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that the company will present at the 5th Annual BMO Private Company Showcase on Friday, October 18, 2019 at 9:40 AM ET.
-
Axial Biotherapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AB-2004 for Treatment of Gastrointestinal Dysfunction and Associated Behavioral Symptoms of Autism Spectrum Disorder
7/16/2019
AB-2004 has demonstrated the ability to repair leaky gut and improve repetitive behavior, anxiety and Autism Spectrum Disorder (ASD)-related sensorimotor gating deficits by removing key microbial metabolites.
-
Axial Biotherapeutics Announces $10M Investment from Taiho Ventures to Access Axial’s Expertise in the Gut-Brain Axis
6/20/2019
Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted therapeutics for neurodegenerative diseases and neurodevelopmental disorders, today announced a direct investment of $10 million from Taiho Ventures, LLC to fund the discovery and development of novel gut-targeted, small molecule approaches in oncology.
-
Axial Biotherapeutics Announces Publication of Preclinical Data Highlighting the Link Between Human Gut Microbiota and Behavioral Symptoms of Autism Spectrum Disorder in Mouse Models
5/31/2019
Axial Biotherapeutics announced the publication of new findings in Cell by Sarkis K. Mazmanian, Ph.D., the Company’s scientific co-founder, and California Institute of Technology researchers, demonstrating that the colonization of germ-free mice with gut microbiota from human donors with Autism Spectrum Disorder (ASD) induces hallmark behaviors of ASD as compared to control, typically-developing (TD) gut microbiota.
-
Axial Biotherapeutics to Participate in Upcoming Conferences in June
5/29/2019
Axial Biotherapeutics announced that the company will participate in the following conferences in June
-
Axial Biotherapeutics Raises $25 Million in Series B Financing
2/27/2019
Funds will be used to advance Axial’s gut-targeted programs in Parkinson’s Disease and Autism Spectrum Disorder
-
BioSpace Movers and Shakers Nov. 5
11/5/2018
Biopharma companies make key appointments to fill leadership positions. Let's take a look! -
Axial Biotherapeutics Strengthens Senior Management Team with Appointment of Jeff Young as Chief Financial Officer
10/30/2018
Axial Biotherapeutics, a biotechnology company building a unique class of microbial-inspired therapeutics for neurological diseases, today announced the appointment of Jeffrey Young as the company’s first Chief Financial Officer (CFO).